IL154378A0 - Compounds for the treatment of addictive disorders - Google Patents
Compounds for the treatment of addictive disordersInfo
- Publication number
- IL154378A0 IL154378A0 IL15437801A IL15437801A IL154378A0 IL 154378 A0 IL154378 A0 IL 154378A0 IL 15437801 A IL15437801 A IL 15437801A IL 15437801 A IL15437801 A IL 15437801A IL 154378 A0 IL154378 A0 IL 154378A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- treatment
- addictive disorders
- addictive
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22571400P | 2000-08-16 | 2000-08-16 | |
| US26361001P | 2001-01-23 | 2001-01-23 | |
| PCT/US2001/025603 WO2002013807A2 (en) | 2000-08-16 | 2001-08-13 | Compounds for the treatment of addictive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL154378A0 true IL154378A0 (en) | 2003-09-17 |
Family
ID=26919847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15437801A IL154378A0 (en) | 2000-08-16 | 2001-08-13 | Compounds for the treatment of addictive disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6841557B2 (de) |
| EP (1) | EP1363634A2 (de) |
| JP (1) | JP2004506621A (de) |
| KR (1) | KR20030024877A (de) |
| AR (1) | AR030364A1 (de) |
| AU (2) | AU2001283393B2 (de) |
| BR (1) | BR0112939A (de) |
| CA (1) | CA2413762A1 (de) |
| CZ (1) | CZ200380A3 (de) |
| EA (1) | EA200300271A1 (de) |
| IL (1) | IL154378A0 (de) |
| MX (1) | MXPA03001472A (de) |
| NO (1) | NO20030717D0 (de) |
| NZ (1) | NZ524741A (de) |
| PE (1) | PE20020288A1 (de) |
| PL (1) | PL363365A1 (de) |
| WO (1) | WO2002013807A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| WO2004032854A2 (en) * | 2002-10-04 | 2004-04-22 | Pharmacia Corporation | Pharmaceutical compositions for treatment of parkinson's disease |
| JP4708795B2 (ja) | 2002-12-20 | 2011-06-22 | ニコノヴァム エービー | 物理的および化学的に安定なニコチン−含有粒状物質 |
| US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
| AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| WO2012039660A1 (en) * | 2010-09-20 | 2012-03-29 | A. Carlsson Research Ab | Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| US4935429A (en) * | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
| US4800204A (en) * | 1987-05-07 | 1989-01-24 | Mueller Peter S | Method of controlling tobacco use |
| US4999382A (en) * | 1988-10-26 | 1991-03-12 | Massachusetts Institute Of Technology | Compositions for treating tobacco withdrawal symptoms and methods for their use |
| US5273975A (en) | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
| ATE117688T1 (de) * | 1989-06-09 | 1995-02-15 | Upjohn Co | Heterozyklische amine mit zns-wirksamkeit. |
| US5051426A (en) * | 1990-03-27 | 1991-09-24 | Parnell Pharmaceuticals, Inc. | Method for effecting withdrawal from drug dependency |
| JPH05507933A (ja) * | 1990-06-29 | 1993-11-11 | ジ・アップジョン・カンパニー | Ｃｎｓおよび抗高血圧活性を有する置換１―（アルコキシフェニル）ピペラジン類 |
| DK0641320T3 (da) | 1991-04-17 | 2001-08-20 | Upjohn Co | Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister |
| TW252979B (de) * | 1992-12-24 | 1995-08-01 | Erba Carlo Spa | |
| BR9405972A (pt) * | 1993-04-06 | 1995-12-12 | Abbott Lab | Composto composição farmaceutica e processo para tratar distúrbios neurológicos psicológicos cardiovasculares cognitivos ou de falta de atenção ou de comportamento que levam ao vicio ou uso de substancias ou uma combinação destas indicações |
| CA2176722A1 (en) | 1993-12-28 | 1995-07-06 | Ruth E. Ten Brink | Heterocyclic compounds for the treatment of cns and cardiovascular disorders |
| GB9407637D0 (en) * | 1994-04-18 | 1994-06-08 | Erba Carlo Spa | Serotoninergic abeo-ergoline derivatives |
| US5874477A (en) * | 1994-08-12 | 1999-02-23 | The University Of Hawaii | Method of treatment for malaria utilizing serotonin receptor ligands |
| AU710984B2 (en) * | 1995-08-11 | 1999-10-07 | Pfizer Inc. | (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin -1-yl)-1-propanolmethanesulfonate trihydrate |
| GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| GB9603226D0 (en) * | 1996-02-15 | 1996-04-17 | Pharmacia Spa | Heterocyclyl-ergoline derivatives |
| US6001848A (en) * | 1996-03-25 | 1999-12-14 | The Regents Of The University Of California | Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele |
| HN1998000118A (es) * | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| GB9723544D0 (en) * | 1997-11-07 | 1998-01-07 | Merck Sharp & Dohme | Therapeutic agents |
| AU2081999A (en) * | 1998-01-13 | 1999-08-02 | Astrazeneca Uk Limited | Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity |
| US6448293B1 (en) * | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
| CN1554341A (zh) * | 2000-04-21 | 2004-12-15 | �������Ŷ���Լ��������˾ | 用于治疗纤维肌痛和慢性疲劳综合症的化合物 |
-
2001
- 2001-08-13 IL IL15437801A patent/IL154378A0/xx unknown
- 2001-08-13 NZ NZ524741A patent/NZ524741A/en unknown
- 2001-08-13 PL PL01363365A patent/PL363365A1/xx not_active Application Discontinuation
- 2001-08-13 CA CA002413762A patent/CA2413762A1/en not_active Abandoned
- 2001-08-13 CZ CZ200380A patent/CZ200380A3/cs unknown
- 2001-08-13 BR BR0112939-2A patent/BR0112939A/pt not_active IP Right Cessation
- 2001-08-13 AU AU2001283393A patent/AU2001283393B2/en not_active Ceased
- 2001-08-13 EP EP01962196A patent/EP1363634A2/de not_active Withdrawn
- 2001-08-13 AU AU8339301A patent/AU8339301A/xx active Pending
- 2001-08-13 JP JP2002518953A patent/JP2004506621A/ja active Pending
- 2001-08-13 MX MXPA03001472A patent/MXPA03001472A/es not_active Application Discontinuation
- 2001-08-13 WO PCT/US2001/025603 patent/WO2002013807A2/en not_active Application Discontinuation
- 2001-08-13 EA EA200300271A patent/EA200300271A1/ru unknown
- 2001-08-13 KR KR10-2003-7002252A patent/KR20030024877A/ko not_active Application Discontinuation
- 2001-08-14 US US09/929,666 patent/US6841557B2/en not_active Expired - Fee Related
- 2001-08-16 PE PE2001000816A patent/PE20020288A1/es not_active Application Discontinuation
- 2001-08-16 AR ARP010103925A patent/AR030364A1/es unknown
-
2002
- 2002-11-15 US US10/295,331 patent/US20030078273A1/en not_active Abandoned
-
2003
- 2003-02-14 NO NO20030717A patent/NO20030717D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002013807A3 (en) | 2003-09-25 |
| AR030364A1 (es) | 2003-08-20 |
| CA2413762A1 (en) | 2002-02-21 |
| NO20030717L (no) | 2003-02-14 |
| BR0112939A (pt) | 2005-11-01 |
| EP1363634A2 (de) | 2003-11-26 |
| MXPA03001472A (es) | 2003-06-06 |
| AU8339301A (en) | 2002-02-25 |
| PE20020288A1 (es) | 2002-03-31 |
| PL363365A1 (en) | 2004-11-15 |
| US6841557B2 (en) | 2005-01-11 |
| KR20030024877A (ko) | 2003-03-26 |
| WO2002013807A2 (en) | 2002-02-21 |
| EA200300271A1 (ru) | 2004-02-26 |
| NZ524741A (en) | 2005-01-28 |
| CZ200380A3 (cs) | 2004-01-14 |
| NO20030717D0 (no) | 2003-02-14 |
| US20030078273A1 (en) | 2003-04-24 |
| JP2004506621A (ja) | 2004-03-04 |
| AU2001283393B2 (en) | 2005-09-22 |
| US20020049206A1 (en) | 2002-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1274444A4 (de) | Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen | |
| IL209842A0 (en) | Compounds for the treatment of metabolic disorders | |
| AU8187701A (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
| GB0007193D0 (en) | Treatment of movrmrnt disorders | |
| ZA200401004B (en) | Combination for the treatment of inflammatory disorders | |
| HK1053058A1 (zh) | 普拉克索用於治療成癮性疾病的用途 | |
| IL150742A0 (en) | Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| GB0008710D0 (en) | Therapeutic compounds | |
| GB0016681D0 (en) | Therapeutic compounds | |
| IL162485A0 (en) | Compounds for the treatment of inflammatory disorders | |
| IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
| AU4498201A (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain | |
| EP1461030A4 (de) | Aminoalkyl-benzofuran-5-ol-verbindungen zur behandlung von glaukom | |
| IL154378A0 (en) | Compounds for the treatment of addictive disorders | |
| CZ20011872A3 (cs) | Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny | |
| ZA200110539B (en) | Oxazinocarbazoles for the treatment of CNS diseases. | |
| SI1468686T1 (sl) | S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj | |
| EP1278538A4 (de) | Cd18-bindender antikörper welche stenose-verwandten erkrankungen verhindern | |
| GB0013105D0 (en) | Therapeutic compounds | |
| GB9918058D0 (en) | Compound for treatment of gi disorders | |
| SI1200447T1 (en) | Oxazinocarbazoles for the treatment of cns diseases | |
| AUPR085100A0 (en) | Novel therapy for hyperlipidaemia-associated disorders | |
| AUPQ696900A0 (en) | Novel therapy for hyperlipidaemia-associated disorders | |
| GB0004998D0 (en) | The treatment of functional gastrointestinal disorders |